✦ 24h Briefing Top Stories World U.S.India Business Technology Science Health Sports Entertainment

Loading

Fetching the latest headlines…

NabkaNews aggregates headlines from thousands of publishers worldwide via Google News, and provides AI-generated summaries and briefings for convenience. Every story links to its original source. We do not host or claim ownership of third-party reporting, and AI summaries may contain errors — always verify with the original source.

24h Briefing Top Stories World U.S.India Business Technology Science Health Sports Entertainment

Disclaimer Privacy Policy Terms of Use

© 2026 NabkaNews · World · U.S. · India — updated continuously. NabkaNews is an independent news aggregator and is not affiliated with any publisher shown.

PRIME-HFrEF Trial: a randomized, double-blind, multi-dose umbilical cord-derived mesenchymal stem cell regimen for heart failure · NabkaNews

← Back to headlines

PRIME-HFrEF Trial: a randomized, double-blind, multi-dose umbilical cord-derived mesenchymal stem cell regimen for heart failure

Nature·Mar 26

This story is reported by Nature. Read what other outlets are saying below, then open the original report for full details.

Full coverage

Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial

Revolutionary Stem Cell Therapy Offers New Hope for Heart Failure Patients

SciTechDaily·Jul 4

Insurers test new way to cut maternity care costs: Bundling

News-Medical·Sep 27

The Man Who Fell From Space: These Are The Last Words Of Cosmonaut Vladimir Komarov

IFLScience·Dec 13

From Tragedy to Triumph, How NASA Reinvented Space Safety

SciTechDaily·Apr 7

View original report at Nature ↗